Saltar ao contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Title
Autor
Subject
Número de Clasificación
ISBN/ISSN
Tag
Buscar
Avanzado
Traficet-EN (CCX282-B), an ora...
Citar
Text this
Enviar este rexistro por email
Imprimir
Exportar rexistro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Permanent link
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Detalles Bibliográficos
Main Authors:
Bekker, P
,
Velde, A
,
Pronk, I
,
Keshav, S
,
Hommes, D
,
Hanauer, S
,
Ungashe, S
,
Zheng, W
,
Wright, K
,
Schall, T
Formato:
Conference item
Publicado:
2007
Existencias
Descripción
Títulos similares
Staff View
Descripción
Summary:
Títulos similares
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
por: Keshav, S, et al.
Publicado: (2007)
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
por: Bekker, P, et al.
Publicado: (2009)
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
por: Keshav, S, et al.
Publicado: (2009)
PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
por: Keshav, S, et al.
Publicado: (2007)
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
por: Bekker, P, et al.
Publicado: (2008)